Montek
Generic Name
Montelukast
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| montek 4 mg chewable tablet | ৳ 6.02 | ৳ 60.20 |
Description
Overview of the medicine
Montek 4 mg Chewable Tablet contains Montelukast, a leukotriene receptor antagonist. It is primarily used for the long-term treatment of asthma and the relief of symptoms of seasonal and perennial allergic rhinitis in children aged 2 to 5 years.
Uses & Indications
Dosage
Adults
Children 2 to 5 years: One 4 mg chewable tablet once daily in the evening. Not for adults; adults typically take 10 mg tablets.
Elderly
Not specifically indicated for elderly patients in this strength; elderly dosage is typically 10 mg.
Renal_impairment
No dosage adjustment is generally required for patients with renal impairment.
How to Take
Take one tablet once daily in the evening, with or without food. The chewable tablet should be chewed completely before swallowing.
Mechanism of Action
Montelukast selectively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing the binding of leukotrienes (LTC4, LTD4, LTE4). These leukotrienes are potent inflammatory mediators released from various cells and contribute to bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment in asthma and allergic rhinitis.
Pharmacokinetics
Onset
Clinical improvement may be seen within one day for asthma and within 1-2 hours for allergic rhinitis, but full effects might take longer.
Excretion
Primarily excreted in the feces via bile (approximately 86%), with minimal renal excretion.
Half life
Approximately 2.7 to 5.5 hours.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations are reached in 2-4 hours. Food does not significantly affect bioavailability.
Metabolism
Extensively metabolized in the liver by cytochrome P450 enzymes (primarily CYP3A4, CYP2C9, and CYP2C8).
Side Effects
Contraindications
- •Hypersensitivity to montelukast or any component of the tablet
Drug Interactions
Rifampin
Strong inducers of CYP3A4, such as rifampin, may decrease montelukast plasma concentrations. Clinical monitoring is advised.
Gemfibrozil
May increase montelukast plasma concentrations. Coadministration should be done with caution.
Phenobarbital
May decrease the area under the curve (AUC) of montelukast by approximately 40%, necessitating clinical monitoring.
Storage
Store at room temperature (below 30°C), away from moisture and light. Keep out of reach of children.
Overdose
Symptoms of overdose usually include abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Treatment is symptomatic and supportive. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Montelukast is excreted in breast milk; caution should be exercised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from manufacturing date.
Availability
Pharmacies, hospitals, clinics
Approval Status
Approved by FDA (USA) and DGDA (Bangladesh)
Patent Status
Generic available (original patent expired)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
